Omalizumab dampens type 2 inflammation in a group of long‐term treated asthma patients and detaches IgE from FcεRI
- 9 October 2018
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 48 (12), 2005-2014
- https://doi.org/10.1002/eji.201847668
Abstract
Even if omalizumab is broadly used in the treatment of severe, allergic asthma, the immunological effects in long‐term treated patients have not been fully elucidated. To this aim a cohort of 15 allergic asthmatic patients treated with omalizumab for at least three years was compared with 12 allergic asthma patients treated with standard therapy. Omalizumab treated asthmatic patients showed lower frequencies of circulating plasmacytoid dendritic cells (DCs), and lower CD154 expression on CD4 T helper cells than the control group. Moreover, basophils and DCs from omalizumab treated patients had lower surface expression of IgE compared to the control group. In a longitudinal evaluation of two patients that started omalizumab treatment, we show that FcεRI free of IgE were evident on basophils just after four weeks of drug administration. Finally, in vitro experiments with basophils obtained from healthy donors confirm that omalizumab is able to detach IgE from high affinity IgE receptors. Collectively these data indicate that long‐term omalizumab treatment dampens type 2 inflammation acting on different cell types that play a pivotal role in the pathogenesis of allergic asthma. Moreover, we have identified a further mechanism of action of omalizumab, such as the ability to detach IgE from its receptor. This article is protected by copyright. All rights reservedKeywords
Funding Information
- ex-60%
This publication has 36 references indexed in Scilit:
- Omalizumab for asthma in adults and childrenCochrane Database of Systematic Reviews, 2014
- Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cellsClinical and Translational Allergy, 2013
- New developments in FcεRI regulation, function and inhibitionNature Reviews Immunology, 2007
- Omalizumab decreased IgE‐release and induced changes in cellular immunity in patients with allergic asthmaAllergy, 2006
- Development of the asthma control test☆A survey for assessing asthma controlJournal of Allergy and Clinical Immunology, 2004
- Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- CD40:CD40L Interactions in X-linked and Non-X-linked Hyper-IgM SyndromesImmunologic Research, 2001
- The pharmacological basis of anti-IgE therapyNature Biotechnology, 2000
- Binding of cynomolgus monkey IgE to a humanized anti-human IgE antibody and human high affinity IgE receptorMolecular Immunology, 1996
- Characterization of Complex Formation by Humanized Anti-IgE Monoclonal Antibody and Monoclonal Human IgEBiochemistry, 1995